Alastair Corbin’s Post

Merck & Daiichi Sankyo US Highlight the P-II (IDeate-Lung01) Study Data of Ifinatamab Deruxtecan to Treat Extensive-Stage Small Cell Lung Cancer at WCLC 2024 #merck #daiichisankyo #ifinatamabderuxtecan #extensivestagesmallcelllungcancer #clinicaltrial #phase2 #ideatelung01

A real-world comparison of cabazitaxel versus ¹⁷⁷Lu-PSMA radiopharmaceutical therapy in metastatic castration-resistant prostate cancer: https://ow.ly/TP2G50U9BjT #NuclearMedicine #RPTherapy #ProstateCancer

We are excited to invite you to our upcoming webinar: “Antibody Drug Conjugates: A Novel Targeted Approach to Cancer Therapy”. The use of ADC's in clinical trials and approved treatments continues to rise at an ever-increasing pace. Hear from industry experts around the successes, advancements, and future direction of ADCs with a focus on precision oncology. https://lnkd.in/dg7bGhy2

VERZENIO (abemaciclib) is an oral, continuously dosed, cyclin-dependent kinase 4/6 (CDK4/6) inhibitor indicated for the treatment of metastatic and high-risk early-stage HR+, HER2- breast cancer. At the American Society of Clinical Oncology (ASCO) 2024 meeting Eli Lilly and Company reported findings from the Phase III study (CYCLONE 2) of VERZENIO (abemaciclib) with ZYTIGA (abiraterone) in patients with mCRPC. DelveInsight Business Research LLP's Exclusive ASCO 2024 Coverage: Unlock Expert Insights and In-Depth Analysis! https://lnkd.in/ggPcVGZ7 #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

Could CAN-2409 change how we treat localized #ProstateCancer? Our phase 3 clinical trial evaluates whether experimental treatment with CAN-2409 added to standard of care radiotherapy results in more patients with intermediate-high risk prostate cancer achieving disease-free survival. The trial is conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Learn more: https://lnkd.in/evZ7S6Zv #ClinicalTrials #ClinicalResearch #BioTech #Immunotherapy

Merck and Daiichi Sankyo US Commence the P-III (IDeate-Lung02) Trial of Ifinatamab Deruxtecan to Treat Small Cell Lung Cancer #merck #daiichisankyo #ifinatamabderuxtecan #smallcelllungcancer #clinicaltrial #phase3 #ideatelung02

Discover the transformative potential of antibody-drug conjugates (ADCs) in targeted cancer therapy. Our latest presentation dives deep into the journey of ADC development, from Paul Ehrlich's early concept of "magic bullets" to their current status as a leading treatment modality. Learn about the intricate bioanalytical challenges, cutting-edge techniques, and regulatory milestones shaping the future of ADCs in oncology. #CancerResearch #ADCs #Bioanalysis #PrecisionMedicine #WuXiAppTec https://hubs.li/Q02zVC290

Merck and Daiichi Sankyo US Provide Data from the P-III (HERTHENA-Lung02) Study of Patritumab Deruxtecan to Treat Non-Small Cell Lung Cancer  #merck #daiichisankyo #patritumabderuxtecan #nonsmallcelllungcancer #clinicaltrial #phase3 #herthenalung02 #egfrmutations

Immunovia AB’s Next Generation Pancreatic Cancer Detection Test Shows Positive Results from Model Development Study #pancreaticcancer #pdac #nextgenerationtest #immraypancandteat #ca19-9 #modeldevelopmentstudy #specificity #sensitivity

LABN Trending News: FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER https://lnkd.in/gsKeN3mU Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study Amgen to Host [...]